VYNDAMAX

Peak

tafamidis

NDAORALCAPSULE
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Clinical Trials (5)

NCT07470866Phase 1Not Yet Recruiting

A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions

Started Mar 2026
24 enrolled
Healthy
NCT07298044Phase 4Not Yet Recruiting

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Started Feb 2026
50 enrolled
Transthyretin Amyloid Cardiomyopathy
NCT06940336Phase 4Recruiting

To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

Started Jun 2025
15 enrolled
Transthyretin Amyloid Polyneuropathy
NCT06705569Phase 1Completed

A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults

Started Dec 2024
22 enrolled
Healthy
NCT06393465N/AActive Not Recruiting

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Started Jun 2024
50 enrolled
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Loss of Exclusivity

LOE Date
Aug 31, 2035
115 months away
Patent Expiry
Aug 31, 2035
Exclusivity Expiry
May 3, 2026

Patent Records (3)

Patent #ExpiryTypeUse Code
7214695
Dec 19, 2026
SubstanceProduct
7214696
Dec 19, 2026
U-2524
9770441
Aug 31, 2035
SubstanceProduct
U-2524